An AI system called Robin analyzed 551 scientific papers in roughly 30 minutes and identified a promising drug candidate for age-related blindness—a task that would have taken human researchers an estimated 540 hours. The Information Technology & Innovation Foundation published a report in June 2026 examining the implications of Robin, which was introduced in a Nature study in May 2026. The foundation argues that systems like Robin could reshape early-stage drug discovery, but only if policymakers create the right data infrastructure, regulatory frameworks, and economic incentives to scale them.

In its proof-of-concept application, Robin identified ripasudil—a therapy primarily used for glaucoma—as a candidate for repurposing to treat dry age-related macular degeneration, the leading cause of blindness in the developed world, and confirmed its effectiveness in laboratory experiments. The report notes that Robin's data-analysis agent scored 47.9 percent on biostatistics tasks compared with only 15.3 percent on bioinformatics tasks, a gap the authors attribute to bioinformatics requiring more multi-step mechanistic reasoning. A 2023 study by the Boston Consulting Group and Wellcome Trust projects that AI-enabled efforts could reduce the time and cost of drug discovery and preclinical stages by 25 to 50 percent. The Boston Consulting Group examined 20 AI-focused pharmaceutical companies and found that 5 of 15 AI-assisted drug candidates that advanced to clinical trials did so in under four years, compared with the historical average of five to six years. One company estimated AI-accelerated drug discovery could save $300 to $400 million per drug, according to a 2019 report by the U.S. Government Accountability Office and the National Academy of Medicine.

The report describes Robin as the first AI system to autonomously discover and validate novel therapeutic candidates within an iterative process that used human-conducted laboratory experiments to test and refine the AI system's hypotheses. Earlier AI tools like AlphaFold2 transformed protein structure prediction, and ActFound improved bioactivity screening, but neither automated the range of tasks Robin did—from literature-grounded hypothesis generation through experimental data analysis and iterative refinement. According to the authors, Robin's approach illustrates "combinatorial synthesis"—the identification of non-obvious connections across disparate areas of the scientific literature that human experts, constrained by specialized knowledge and disciplinary boundaries, can miss.

The report explains that Robin's contribution reveals both the promise and limits of current AI systems in drug development. These systems excel at pattern recognition in large datasets—screening compound libraries, predicting protein structures, flagging candidate targets based on statistical associations. Where they face greater challenges is causal inference: determining not merely that two variables are correlated, but why a biological relationship exists and what mechanisms underlie it. That gap matters in drug development, where understanding the causal pathway from target to compound to therapeutic effect is critical. Robin's emergence also responds to genuine productivity concerns: FDA novel drug approvals have held roughly steady over the past decade even as research and development investment has grown substantially.

The report argues that realizing the potential of systems like Robin at scale will depend on four policy areas: sustained public investment in shared data infrastructure through programs like the National Institute of Health's Bridge2AI and All of Us Research Program; risk-based regulatory frameworks that clarify FDA review processes for discovery-stage AI tools; commercial incentives that don't compress the returns motivating private investment, warning that drug-pricing policies like provisions of the Inflation Reduction Act can dampen investment in early-stage research; and investment in automated laboratory infrastructure like cloud labs and robotic experimentation platforms. The foundation's bottom line is clear: AI-driven efficiency gains offer a path to addressing rising drug development costs without sacrificing the economic incentives that fuel innovation in the first place.